Hippocrates stated there is 'a great difference in the constitution of individuals.' Despite the truth of his observation it was rarely considered over the next two millennia with the exception of occasional and often erroneous reports of medication responses related to varied external patient characteristics such as skin tone or hair color. Recent advances in molecular biology have enabled researchers to identify associations between individuals' genetic profiles and drug responses. Pharmacogenetics is the study of inherited differences in drug metabolism and response [1]. Pharmacogenetic research seeks to identify genetic variants that will enable clinicians to tailor therapeutic regimens for individual patients to maximize drug effectiveness while minimizing adverse side effects.
nucleotide pairing that occurs least frequently in a population. Allelic variation may have functional consequences that can significantly affect opiate metabolism, efficacy, and side effects. Furthermore, because every individual carries two copies of most genes (one inherited from each parent), the clinical effects of a mutation may be magnified when specific allelic variation occurs on copies of both chromosomes (homozygous expression), rather than on just one of the two inherited chromosomes (heterozygous expression). For example, allelic variation within the catechol-O-methyltransferase (COMT) gene has been associated with both opiate-related analgesia and sedation, with homozygotes having magnified effects compared with heterozygotes [4] [5] [6] . Although most studies to date have assessed the association between individual SNPs selected from within a single gene region and opiate effects, some recent studies have also begun to investigate the relation between gene-gene interactions and opiate responses. To make things even more complex, gene associations should be evaluated in well phenotyped populations that are of homogenous ethnic admixture, as SNP frequencies can vary in different racial groups. Furthermore, identified SNP to phenotype associations should be statistically adjusted for potential environmental influences on phenotype such as those imposed by patient demographics, comorbidities and medication use. Thus, it should be emphasized that the final observed patient phenotypic response with regards to opiate efficacy and side effects results from a complex interplay of genetic and environmental variables [7 ,8] .
Candidate gene studies
One commonly used technique to identify genetic risk factors for complex disorders such as pain is the candidate gene approach, which directly tests the effects of genetic variants of a potentially contributing gene in an association study.
Opioid receptor m-1 gene
Opioid receptors are G-protein-coupled receptors that are essential targets for opioid analgesia. Although all opioid receptors mediate opiate effects, m receptors have a primary role in analgesia. The OPRM1 gene on chromosome 6q24-25 codes for four m opioid receptor subtypes (MOR-1, MOR-1A, MOR-1X, and MOR-1O) and contains more than 800 SNPs. To date, most studies have focused on the OPRM1 A118G SNP (10-15% minor allele frequency in Caucasians), which results in a substitution of asparagine for aspartate at position 40 of the extracellular N-terminal domain (N40D) of the m receptor [9] . In both cancer and perioperative patients, carriers of the wild-type OPRM1 A118G variant have significantly reduced analgesic requirements for either intravenous morphine or its metabolite morphine-6-glucuronide (M6G) [7 ,9-13] . These studies suggested that the OPRM1 A118G SNP could be used to predict and therefore plan adequate opioid dosages for individualized pain treatment and postoperative monitoring [14] .
Several studies have also assessed the association between the OPRM1 A118G SNP and postoperative pain control with neuraxially administered opioids (Table 1) . Sia et al. [15 ] recently assessed the A118G SNP for its association with adequacy of postoperative analgesia after administering 0.1 mg of intrathecal morphine to 588 women of Han Chinese descent who were undergoing cesarean section. The women were assessed postoperatively for interindividual differences in reported pain score, total 24 h dose of self-administered postoperative IV morphine, and incidence of postoperative nausea. Twenty-four hour postoperative total IV morphine administration differed significantly by the A118G genotype (P ¼ 0.001) when comparing the AA homozygous wild-type group (mean dose ¼ 5.9 mg) with the AG heterozygous group (mean dose ¼ 8.0 mg) and GG homozygous group (mean dose ¼ 9.4 mg) [15 ] . In contrast, the AA homozygous wild-type group was associated with the Effect of genetic factors on opioid action Kosarac et al. 477 [16] . This study also noted significantly lower 24 h postoperative opioid requirements in the A118G SNP wild-type carriers. A third study by Landau et al. [17] recently assessed the association between the A118G SNP and analgesic efficacy of intrathecal fentanyl in 224 nulliparous laboring women who received combined spinal-epidural for labor analgesia. In contrast to the two previously mentioned studies that found that individuals who were AA carriers required less neuraxial opiates, Landau et al. found that homozygote carriers of the wild-type A118G SNP had a significantly higher intrathecal fentanyl median effective dose (ED 50 ) for labor analgesia (P < 0.001). It is possible that this may reflect a difference in neuraxial responsiveness to morphine versus fentanyl. Together, these findings suggest that larger randomized studies involving preoperative patient screening for the OPRM1 A118G SNP and alternate opioid pain management strategies are warranted.
Several recent studies have sought to elucidate the molecular mechanisms by which the OPRM1 A118G SNP may influence opioid responsiveness. One area of investigation concerns how opioid receptors interact with the hypothalamic-pituitary-adrenal axis regarding release of corticotropin releasing hormones and subsequent release of adrenocorticotropic hormone (ACTH) and cortisol. In a study of 29 healthy individuals who received the m opioid receptor blocker naloxone versus placebo, individuals with one or two copies of the G allele showed a significantly greater cortisol response to naloxone than did the wild-type homozygotes (P < 0.03) [18] . However, this study needs to be replicated as it was small and contained patients of multiple ethnic backgrounds, a factor that can confound gene association study results when SNP frequencies or phenotypic outcomes vary between the ethnic groups being studied [18] .
Oertel et al. [19] found that the presence of the wild-type OPRM1 A118G allele was associated with decreased requirements for alfentanil induced analgesia but was also associated with increased respiratory depression. Four heterozygous and six homozygous carriers of the variant OPRM1 118G allele received a computerized infusion of alfentanil to achieve target effect-site concentrations of 0, 33.33, 66.67 and 100 ng/ml. At each concentration level, analgesia was assessed by means of electrically and chemically induced pain, and respiratory depression was quantified by hypercapnic challenge and breathing frequency. Higher alfentanil concentrations were needed in homozygous carriers than in wild-type individuals (2-4 times) to produce the same degree of analgesia, whereas 10-12 times higher alfentanil concentrations were needed to produce the same degree of respiratory depression. Thus, the OPRM1 A118G SNP affects both analgesic and respiratory depressive effects of opiates. [20] . The poor metabolizer phenotype occurs in 7-10% of Caucasians [9] . Individuals carrying one or two copies of a wild-type (functional) CYP2D6 gene variant are extensive metabolizers (metabolize CYP2D6 substrates normally) and tend to have better analgesic responses to opiates than poor metabolizers. Duplication of the CYP2D6 gene results in the ultra-rapid metabolizer phenotype. Individuals with the ultra-rapid metabolizer phenotype have more than two functional copies of wild-type alleles, resulting in rapid opiate metabolism that can lead to analgesic failure or exaggerated opiate side effects depending upon whether the prodrug or its metabolite is most active [9, 21] . However, CYP2D6 activity is not affected by genetics alone. Concurrent administration of medications that are also metabolized by the cytochrome P450 system (drugs that can induce or inhibit CYP2D6 enzyme activity) can imitate genetically mediated alterations in opiate metabolism. For example, paroxetin, amiodarone, cimetidine, and ranitidine are well known CYP2D6 inhibitors. Furthermore, factors such as impaired renal or hepatic metabolism can lead to high plasma levels of active opiate drug, particularly in ultra-rapid metabolizers receiving opiates with an active metabolite. Thus, assessment of CYP2D6 related opiate metabolism phenotypes and associated responses in opiate analgesic action and side effects should seek to take into account both genetic and nongenetic influences on plasma opiate concentrations and related physiologic responses.
CYP2D6 metabolizes tramadol to the analgesic opioid receptor agonist O-desmethyltramadol (O-DT) that has a higher m opioid receptor affinity and analgesic efficacy than the tramadol prodrug. Stamer et al. [22] genotyped 174 patients who received IV tramadol for postoperative analgesia after major abdominal surgery. The variability of response to O-DT was closely correlated to CYP2D6 genotypes. Specifically, the poor metabolizer CYP2D6 genotype was associated with poor analgesia in response to tramadol administration, with nonresponse rates to tramadol treatment four-fold higher in poor metabolizer individuals than in individuals with other functional CYP2D6 genotypes (P < 0.001) [22] . Similarly, Foster et al. [20] described a patient who experienced inadequate pain control when multiple different opiates were administered after a T12 vertebral injury. This patient was found to have the CYP2D6 4Ã/4Ã and CYP2C19 1Ã/2Ã genotypes, which correspond to the CYP2D6 poor metabolizer and CYP2C19 extensive metabolizer phenotypes, respectively.
Patients expressing the CYP2D6 ultra-rapid metabolizer genotypes can also have atypical responses to opioid treatment. For example, a 66-year-old man with renal insufficiency and a CYP2D6 ultra-rapid metabolizer genotype underwent surgery for recurring renal carcinoma and developed postoperative respiratory depression while receiving tramadol intravenously via patient controlled analgesia [21] . Similarly, Kirchheiner et al. [23] compared carriers of the CYP2D6 ultra-rapid metabolizer and extensive metabolizer genotypes following treatment with tramadol. Patients expressing the CYP2D6 ultra-rapid metabolizer genotype had consistently higher plasma levels of OD-T and better pain control than carriers of the extensive metabolizer genotype; however, carriers of the CYP2D6 ultra-rapid metabolizer genotype had more nausea secondary to tramadol than patients expressing the CYP2D6 extensive metabolizer genotype. In a different study, Kircheiner et al. [24] compared plasma morphine metabolite concentrations and sedation side effects in individuals given codeine (11 carriers of the CYP2D6 ultra-rapid metabolizer genotype and 12 carriers of the extensive metabolizer genotype) and found that ultra-rapid metabolizer individuals had significantly higher plasma morphine concentrations and significantly more sedation than individuals with the extensive metabolizer genotype. Together, these data suggest that patients expressing CYP2D6 ultra-rapid metabolizer genotypes may be at greater risk for opiate-related adverse side effects, and that patients with CYP2D6 genotypes related to the ultra-rapid metabolizer phenotype might benefit from lower dosing of drugs such as tramadol or codeine that are metabolized from prodrug to active metabolite, particularly if patients have renal insufficiency.
ATP-binding cassette sub-family B member-1 gene
Drug transporters are structural proteins involved in opioid absorption, distribution, and elimination. One of the drug transport protein families that play a major role in opiate pharmacokinetics is the ATP binding cassette (ABC) superfamily of efflux transporters. The ABCB1 gene, also referred to as the multidrug resistance-1 (MDR1) gene, is highly polymorphic and encodes P-glycoprotein (P-gp) 170. P-gp 170 is a protein transporter that pumps drugs from intracellular to extracellular domains in various tissues including the central nervous system. P-gp 170 acts as a blood-brain barrier 'gatekeeper' that affects both clinical opioid efficacy and safety by regulating opiate accumulation in the central nervous system.
Levran et al. [25 ] assessed the association between nine SNPs in the ABCB1 gene and methadone dose requirements in 98 methadone maintained patients and found a significantly higher minor allele frequency for the C1236T coding SNP (rs1128503; odds ratio ¼ 6.67, P ¼ 0.0325 after adjusting for multiple hypothesis testing) in the higher (>150 mg/day) versus lower dose ( 150 mg/ day) methadone maintenance groups. Furthermore, individuals who carried two copies of the minor allele for all three assessed ABCB1 coding SNPs (TT-TT-TT; rs1128503, rs2032582, and rs1045642) were five times more likely to be in the high dose methadone maintenance group than individuals carrying any other allele pattern (P ¼ 0.034), and individuals who were heterozygous for all three of these SNPs had an approximately three-fold chance of stabilizing at the 'lower' methadone dose than individuals carrying any other allele pattern (P ¼ 0.014). These data suggest that variations within the ABCB1 gene may significantly influence the overall methadone dose required to prevent withdrawal symptoms and relapse in populations being treated for heroin addiction. However, another study found no significant relation between total methadone dosage requirements and ABCB1 haplotypes, suggesting that further studies in larger, well phenotyped patients undergoing heroin recovery are needed to determine the influence of ABCB1 gene variation on total stable methadone dose required to prevent withdrawal and relapse [26] .
Catechol-O-methyltransferase (COMT) gene
Catecholamines such as dopamine and norepinephrine are secondarily involved in the modulation of pain and are in part metabolized by the catechol-O-methyltransferase (COMT) enzyme. Thus, variability in the COMT gene on chromosome 22 may contribute to variability in analgesic responses to opioids as well as differences in susceptibility to opioid dependence and addiction. The COMT gene contains a frequent coding SNP (G472A) that codes for a Val158Met substitution that is known to result in reduced COMT enzyme activity. Oosterhuis et al. [27 ] found that frequencies of the G472A SNP as well as other novel SNPs identified within the same exon of the COMT gene varied significantly (P ¼ 0.029) between Caucasian (n ¼ 173), Hispanic (n ¼ 122), and African descent (n ¼ 100) individuals. Oosterhuis et al. [27 ] assessed the COMT SNPs in each ethnic stratum for association with a history of opioid dependence and found that the G472A SNP was marginally associated with opioid addiction in Hispanic women (P ¼ 0.049) and in Hispanic men and women assessed together (P ¼ 0.053) before adjusting for multiple hypothesis testing. Given the small number of individuals enrolled in three ethnic groups, this study suggests that larger studies may be warranted to assess the associations between COMT SNPs and opiate addiction. In another study, Rakvag et al. [5] investigated 11 COMT SNPs in 197 Caucasian patients receiving oral morphine treatment for cancer pain. After multivariate adjustments they found that patients with the most frequent COMT haplotype involving the 11 genotyped SNPs (34.5% frequency) required lower daily morphine doses than patients with the other COMT haplotypes. This study suggests that genetic variability within the COMT gene is significantly associated with morphine efficacy in patients with cancer pain and highlights that haplotypes sometimes are more powerfully predictive of outcomes than individual SNPs [5] .
Joint gene effects
Few studies have attempted to assess the joint effects of variations within two or more gene regions in relation to opioid response (Table 2) [4, 6, 28, 29] . Recently, 145 cancer patients of Italian origin undergoing morphine therapy were genotyped for the ABCB1/MDR1 C3435T and OPRM1 A118G SNPs [28] . Pain relief variability over a 2-month period with morphine therapy was significantly (P < 0.0001) associated with both polymorphisms. When the two SNPs were considered together, the association between these polymorphisms and pain relief became even more significant (P < 0.00001). Three groups of morphine responders were related to differing combinations of the ABCB1/MDR1 and OPRM1 SNP genotypes: nonresponders were homozygous for the major allele of the MDR1 SNP and the minor allele of the OPRM1I SNP, whereas strong responders were homozygous for the opposite alleles of the two SNPs. Patients with intermediate genotypes were intermediate responders to morphine therapy [29] . Another study by ReyesGibby et al. [6] assessed the joint effects of the OPRM1 A118G and COMT Val158Met SNPs for predicting . In contrast, the COMT -4873G SNP allele was significantly associated with increased central side effects. These observed genetic associations with centrally mediated morphine side effects were unrelated to administered morphine or serum morphine or morphine metabolite concentrations. These data suggest that variants in multiple genes may be usefully assessed together to predict opiate response.
Summary
Growing pharmacogenetic data make it evident that many opiate related phenomena have an underlying genetic influence. Genetic variation may significantly affect opiate absorption, distribution, metabolism, excretion and toxicity. Although pharmacogenetics has the potential to increase drug efficacy, prevent drug toxicity, and to eliminate costly and ineffective drug alternatives, many gene-drug associations at present are poorly understood and of unclear clinical significance. Thus, there remains at present a strong need for prospective, sufficiently powered gene association studies conducted and validated in well defined, highly phenotyped populations.
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